[Reversible posterior leukoencephalopathy post-chemotherapy with carboplatin and paclitaxel]

Mathieu Jamelot; Maxime Fontanilles; Yvan Vaschalde

doi:10.1016/j.bulcan.2019.06.004

[Reversible posterior leukoencephalopathy post-chemotherapy with carboplatin and paclitaxel]

Bull Cancer. 2019 Dec;106(12):1191-1195. doi: 10.1016/j.bulcan.2019.06.004. Epub 2019 Aug 28.

[Article in French]

Authors

Mathieu Jamelot¹, Maxime Fontanilles², Yvan Vaschalde³

Affiliations

¹ Centre Henri-Becquerel, oncologie, 1, rue d'Amiens, 76000 Rouen, France; Université de Rouen, faculté de médecine, 22, boulevard Gambetta, 76000 Rouen, France. Electronic address: mathieu.jamelot@yahoo.fr.
² Centre Henri-Becquerel, oncologie, 1, rue d'Amiens, 76000 Rouen, France; Université de Rouen, faculté de médecine, 22, boulevard Gambetta, 76000 Rouen, France.
³ Hôpital Jacques-Monod, neurologie, 29, avenue Pierre-Mendès 76290 Montivilliers, France.

PMID: 31472945
DOI: 10.1016/j.bulcan.2019.06.004

No abstract available

Keywords: Cancer; Carboplatin-paclitaxel; Carboplatine-paclitaxel; Chemotherapy; Chimiothérapie; Leucoencéphalopathie postérieure réversible; Neurologie; Neurology; Reversible Posterior Leukoencephalopathy.

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Carboplatin / administration & dosage
Carboplatin / adverse effects
Carcinoma, Squamous Cell / drug therapy*
Carcinoma, Squamous Cell / secondary
Diagnosis, Differential
Fatal Outcome
Female
Humans
Middle Aged
Paclitaxel / administration & dosage
Paclitaxel / adverse effects
Posterior Leukoencephalopathy Syndrome / chemically induced*
Posterior Leukoencephalopathy Syndrome / diagnostic imaging
Uterine Cervical Neoplasms / drug therapy*
Uterine Cervical Neoplasms / pathology

Substances

Carboplatin
Paclitaxel